Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
The purpose of our study was to identify risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH). Of 44 patients receiving DA-EPOCH at our institution, 3 (7%) developed PRES. The patients who developed PRES were more likely to have a pre-existing central nervous system insult, fluid status or electrolytes abnormalities, and hypertension.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Hypertension | Leukemia | Lymphoma | Myeloma | Prednisone | Study